Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23
- PMID: 11737582
- DOI: 10.1046/j.1523-1755.2001.00064.x
Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23
Abstract
Background: The gene for the renal phosphate wasting disorder autosomal-dominant hypophosphatemic rickets (ADHR) is FGF23, which encodes a secreted protein related to the fibroblast growth factors (FGFs). We previously detected missense mutations R176Q, R179W, and R179Q in FGF23 from ADHR kindreds. The mutations replace R residues within a subtilisin-like proprotein convertase (SPC) cleavage site 176RHTR-179 (RXXR motif). The goal of these studies was to determine if the ADHR mutations lead to protease resistance of FGF-23.
Methods: The ADHR mutations were introduced into human FGF-23 cDNA clones with or without an N-terminal FLAG tag by site-directed mutagenesis and were transiently transfected into HEK293 cells. Protein expression was determined by Western analyses.
Results: Antibodies directed toward the C-terminal portion of FGF-23 revealed that the native FGF-23 protein resolved as 32 kD and 12 kD species in HEK293 conditioned media; however, the three mutated proteins were detected only as the 32 kD band. An N-terminal FLAG-tagged native FGF-23 resolved as two bands of 36 kD and 26 kD when detected with a FLAG antibody, whereas the R176Q mutant resolved primarily as the 36 kD protein species. Cleavage of FGF-23 was not enhanced by extracellular incubation of FGF-23 with HEK293 cells. Native and mutant FGF-23s bound heparin.
Conclusions: FGF-23 proteins containing the ADHR mutations are secreted, and produce polypeptides less sensitive to protease cleavage than wild-type FGF-23. Therefore, the ADHR mutations may protect FGF-23 from proteolysis, thereby potentially elevating circulating concentrations of FGF-23 and leading to phosphate wasting in ADHR patients.
Similar articles
-
Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.Endocrinology. 2002 Aug;143(8):3179-82. doi: 10.1210/endo.143.8.8795. Endocrinology. 2002. PMID: 12130585
-
The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency.J Biol Chem. 2003 Mar 14;278(11):9843-9. doi: 10.1074/jbc.M210490200. Epub 2003 Jan 7. J Biol Chem. 2003. PMID: 12519781
-
The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting.J Clin Endocrinol Metab. 2001 Feb;86(2):497-500. doi: 10.1210/jcem.86.2.7408. J Clin Endocrinol Metab. 2001. PMID: 11157998
-
FGF23 and disorders of phosphate homeostasis.Cytokine Growth Factor Rev. 2005 Apr;16(2):221-32. doi: 10.1016/j.cytogfr.2005.01.002. Epub 2005 Feb 5. Cytokine Growth Factor Rev. 2005. PMID: 15863037 Review.
-
Earlier Onset in Autosomal Dominant Hypophosphatemic Rickets of R179 than R176 Mutations in Fibroblast Growth Factor 23: Report of 20 Chinese Cases and Review of the Literature.Calcif Tissue Int. 2019 Nov;105(5):476-486. doi: 10.1007/s00223-019-00597-y. Epub 2019 Sep 5. Calcif Tissue Int. 2019. PMID: 31486862 Review.
Cited by
-
Osteocyte regulation of phosphate homeostasis and bone mineralization underlies the pathophysiology of the heritable disorders of rickets and osteomalacia.Bone. 2013 Jun;54(2):213-21. doi: 10.1016/j.bone.2013.01.046. Epub 2013 Feb 9. Bone. 2013. PMID: 23403405 Free PMC article. Review.
-
Exploring mechanisms of FGF signalling through the lens of structural biology.Nat Rev Mol Cell Biol. 2013 Mar;14(3):166-80. doi: 10.1038/nrm3528. Epub 2013 Feb 13. Nat Rev Mol Cell Biol. 2013. PMID: 23403721 Free PMC article. Review.
-
Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology.Cold Spring Harb Perspect Biol. 2013 Jun 1;5(6):a015958. doi: 10.1101/cshperspect.a015958. Cold Spring Harb Perspect Biol. 2013. PMID: 23732477 Free PMC article. Review.
-
Benefits of molecular pathology in the diagnosis of musculoskeletal disease : Part II of a two-part review: bone tumors and metabolic disorders.Skeletal Radiol. 2010 Mar;39(3):213-24. doi: 10.1007/s00256-009-0758-y. Epub 2009 Aug 11. Skeletal Radiol. 2010. PMID: 19669759 Review.
-
Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease.Cell Tissue Res. 2010 Oct;342(1):1-11. doi: 10.1007/s00441-010-1024-2. Epub 2010 Aug 24. Cell Tissue Res. 2010. PMID: 20730630 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases